Company Description
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.
The company was founded in 2017 and is headquartered in Bethesda, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Matthias Alder LIC. IUR., LL.M. |
Contact Details
Address: 4800 Hampden Lane, Suite 200 Bethesda, Maryland 20814 United States | |
| Phone | (301) 500-1556 |
| Website | gaintherapeutics.com |
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| Employer ID | 85-1726310 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Khalid Islam Ph.D. | Founder and Chairman |
| Matthias Alder LIC. IUR., LL.M. | President, Chief Executive Officer and Director |
| Gene Mack M.B.A. | Chief Financial Officer |
| Dr. Manolo Bellotto Ph.D. | GM and Chief Strategy Officer |
| Dr. Joanne Taylor Ph.D. | Senior Vice President of Research |
| Dr. Terenzio Ignoni Pharm.D. | Senior Vice President of Technical Operations |
| Dr. Jonas Hannestad M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Jan 31, 2024 | 8-K | Current Report |